These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 23644972

  • 1. Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
    Peyrin-Biroulet L.
    Am J Gastroenterol; 2013 May; 108(5):859-60. PubMed ID: 23644972
    [No Abstract] [Full Text] [Related]

  • 2. Guidelines for the management of inflammatory bowel disease in adults.
    Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology.
    Gut; 2004 Sep; 53 Suppl 5(Suppl 5):V1-16. PubMed ID: 15306569
    [No Abstract] [Full Text] [Related]

  • 3. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr 28; 147(17):58-9. PubMed ID: 15903063
    [No Abstract] [Full Text] [Related]

  • 4. Refractory inflammatory bowel disease in children.
    Oliva-Hemker M, Escher JC, Moore D, Dubinksy M, Hildebrand H, Koda YK, Murch S, Sandhu B, Seo JK, Tanzi MN, Warner B, Relapsing Inflammatory Bowel Diseases Working Group.
    J Pediatr Gastroenterol Nutr; 2008 Aug 28; 47(2):266-72. PubMed ID: 18664886
    [No Abstract] [Full Text] [Related]

  • 5. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB.
    Gut; 2007 Sep 28; 56(9):1181-3. PubMed ID: 17698862
    [Abstract] [Full Text] [Related]

  • 6. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, Cardillo C.
    Clin Pharmacol Ther; 2008 Jan 28; 83(1):70-6. PubMed ID: 17507924
    [Abstract] [Full Text] [Related]

  • 7. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun 28; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 8. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
    Peng JC, Shen J, Ran ZH.
    J Dig Dis; 2014 Nov 28; 15(11):585-90. PubMed ID: 25251263
    [Abstract] [Full Text] [Related]

  • 9. Infliximab in ulcerative colitis.
    Aberra FN, Lichtenstein GR.
    Gastroenterol Clin North Am; 2006 Dec 28; 35(4):821-36. PubMed ID: 17129815
    [Abstract] [Full Text] [Related]

  • 10. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S, Angelucci E.
    Gastroenterol Clin Biol; 2009 Jun 28; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [Abstract] [Full Text] [Related]

  • 11. [Chronic inflammatory bowel disease: Crohn's disease and ulcerative colitis].
    Fiasse R, Denis MA, Dewit O.
    J Pharm Belg; 2010 Mar 28; (1):1-9. PubMed ID: 20432590
    [Abstract] [Full Text] [Related]

  • 12. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM, Schmidt D, Karlén P.
    Lakartidningen; 2010 Mar 28; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract] [Full Text] [Related]

  • 13. Anti-TNF-alpha treatment strategies: results and clinical perspectives.
    D'Haens G.
    Gastroenterol Clin Biol; 2009 Jun 28; 33 Suppl 3():S209-16. PubMed ID: 20117344
    [Abstract] [Full Text] [Related]

  • 14. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar 28; 1(3):253-5. PubMed ID: 10566038
    [No Abstract] [Full Text] [Related]

  • 15. [Inflammatory bowel disease: an overview].
    Herrlinger K.
    Med Monatsschr Pharm; 2013 Nov 28; 36(11):402-8; quiz 409. PubMed ID: 24640117
    [Abstract] [Full Text] [Related]

  • 16. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW, Fedorak RN.
    Gastroenterol Clin North Am; 2010 Sep 28; 39(3):543-57. PubMed ID: 20951917
    [Abstract] [Full Text] [Related]

  • 17. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P, Van Assche G, Vermeire S.
    Aliment Pharmacol Ther; 2006 Feb 15; 23(4):451-63. PubMed ID: 16441465
    [Abstract] [Full Text] [Related]

  • 18. [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease].
    Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F, Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU).
    Gastroenterol Hepatol; 2013 Mar 15; 36(3):127-46. PubMed ID: 23433780
    [No Abstract] [Full Text] [Related]

  • 19. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ, Cominelli F.
    Adv Intern Med; 1998 Mar 15; 43():143-74. PubMed ID: 9506181
    [No Abstract] [Full Text] [Related]

  • 20. Targeting TNF-α for the treatment of inflammatory bowel disease.
    Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S.
    Expert Opin Biol Ther; 2014 Jan 15; 14(1):75-101. PubMed ID: 24206084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.